Edwards Lifesciences (EW) Operating Leases (2019 - 2026)

Edwards Lifesciences' Operating Leases history runs 8 years deep, the most recent figure standing at $80.1 million for Q1 2026.

• In Q1 2026, Operating Leases rose 2.82% year-over-year to $80.1 million; the TTM figure through Mar 2026 stood at $80.1 million (up 2.82% YoY), while the FY2025 annual figure was $82.6 million, up 4.69% from the prior year.
• Operating Leases was $80.1 million for Q1 2026 at Edwards Lifesciences, down from $82.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $95.0 million in Q4 2022 to a low of $63.5 million in Q2 2022.
• Historically, Operating Leases has averaged $76.0 million across 5 years, with a median of $77.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Leases surged 37.48% in 2022, then declined 11.41% in 2025.
• A 5-year view of Operating Leases shows it stood at $95.0 million in 2022, then fell by 7.26% to $88.1 million in 2023, then slipped by 10.44% to $78.9 million in 2024, then grew by 4.69% to $82.6 million in 2025, then decreased by 3.03% to $80.1 million in 2026.
• The last three Operating Leases figures came in at $80.1 million (Q1 2026), $82.6 million (Q4 2025), and $75.3 million (Q3 2025), per Business Quant data.